Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony.

Literature DB >> 10959714

Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony.

R W Herzog, V R Arruda, T H Fisher, M S Read, T C Nichols, K A High.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2000 PMID： 10959714 PMCID： PMC3938110

Source DB: PubMed Journal: Thromb Haemost ISSN： 0340-6245 Impact factor: 5.249

× No keyword cloud information.

10 in total

1. Endogenous canine FIX antigen exists in Chapel Hill strain hemophilia B canine.

Authors: H Chao; C E Walsh
Journal: Thromb Haemost Date: 1999-10 Impact factor: 5.249

2. High resolution two-dimensional electrophoresis of proteins.

Authors: P H O'Farrell
Journal: J Biol Chem Date: 1975-05-25 Impact factor: 5.157

3. Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs.

Authors: B Fang; H Wang; G Gordon; D A Bellinger; M S Read; K M Brinkhous; S L Woo; R C Eisensmith
Journal: Gene Ther Date: 1996-03 Impact factor: 5.250

4. Thrombolamban, the 22-kDa platelet substrate of cyclic AMP-dependent protein kinase, is immunologically homologous with the Ras family of GTP-binding proteins.

Authors: T E White; J C Lacal; B Reep; T H Fischer; E G Lapetina; G C White
Journal: Proc Natl Acad Sci U S A Date: 1990-01 Impact factor: 11.205

5. Isolation and characterization of canine factor IX.

Authors: Y Sugahara; J Catalfamo; M Brooks; E Hitomi; S P Bajaj; K Kurachi
Journal: Thromb Haemost Date: 1996-03 Impact factor: 5.249

6. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.

Authors: M A Kay; S Rothenberg; C N Landen; D A Bellinger; F Leland; C Toman; M Finegold; A R Thompson; M S Read; K M Brinkhous
Journal: Science Date: 1993-10-01 Impact factor: 47.728

7. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.

Authors: R O Snyder; C Miao; L Meuse; J Tubb; B A Donahue; H F Lin; D W Stafford; S Patel; A R Thompson; T Nichols; M S Read; D A Bellinger; K M Brinkhous; M A Kay
Journal: Nat Med Date: 1999-01 Impact factor: 53.440

8. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.

Authors: R W Herzog; E Y Yang; L B Couto; J N Hagstrom; D Elwell; P A Fields; M Burton; D A Bellinger; M S Read; K M Brinkhous; G M Podsakoff; T C Nichols; G J Kurtzman; K A High
Journal: Nat Med Date: 1999-01 Impact factor: 53.440

9. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.

Authors: M A Kay; C N Landen; S R Rothenberg; L A Taylor; F Leland; S Wiehle; B Fang; D Bellinger; M Finegold; A R Thompson
Journal: Proc Natl Acad Sci U S A Date: 1994-03-15 Impact factor: 11.205

10. Canine hemophilia B resulting from a point mutation with unusual consequences.

Authors: J P Evans; K M Brinkhous; G D Brayer; H M Reisner; K A High
Journal: Proc Natl Acad Sci U S A Date: 1989-12 Impact factor: 11.205

10 in total

11 in total

1. Prolonged Expression of Secreted Enzymes in Dogs After Liver-Directed Delivery of Sleeping Beauty Transposons: Implications for Non-Viral Gene Therapy of Systemic Disease.

Authors: Elena L Aronovich; Kendra A Hyland; Bryan C Hall; Jason B Bell; Erik R Olson; Myra Urness Rusten; David W Hunter; N Matthew Ellinwood; R Scott McIvor; Perry B Hackett
Journal: Hum Gene Ther Date: 2017-05-19 Impact factor: 5.695

Review 2. Animal models of hemophilia.

Authors: Denise E Sabatino; Timothy C Nichols; Elizabeth Merricks; Dwight A Bellinger; Roland W Herzog; Paul E Monahan
Journal: Prog Mol Biol Transl Sci Date: 2012 Impact factor: 3.622

3. Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.

Authors: T C Nichols; H W G Franck; C T Franck; N De Friess; R A Raymer; E P Merricks
Journal: J Thromb Haemost Date: 2012-03 Impact factor: 5.824

4. Portal vein delivery of viral vectors for gene therapy for hemophilia.

Authors: Alexandra Sherman; Alexander Schlachterman; Mario Cooper; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Roland W Herzog; Timothy C Nichols
Journal: Methods Mol Biol Date: 2014

5. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.

Authors: Valder R Arruda; Joerg Schuettrumpf; Roland W Herzog; Timothy C Nichols; Nancy Robinson; Yasmin Lotfi; Federico Mingozzi; Weidong Xiao; Linda B Couto; Katherine A High
Journal: Blood Date: 2003-09-11 Impact factor: 22.113

6. Muscle Gene Therapy for Hemophilia.

Authors: Denise E Sabatino; Valder R Arruda
Journal: J Genet Syndr Gene Ther Date: 2012-05-07

7. Liver-directed lentiviral gene therapy in a dog model of hemophilia B.

Authors: Alessio Cantore; Marco Ranzani; Cynthia C Bartholomae; Monica Volpin; Patrizia Della Valle; Francesca Sanvito; Lucia Sergi Sergi; Pierangela Gallina; Fabrizio Benedicenti; Dwight Bellinger; Robin Raymer; Elizabeth Merricks; Francesca Bellintani; Samia Martin; Claudio Doglioni; Armando D'Angelo; Thierry VandenDriessche; Marinee K Chuah; Manfred Schmidt; Timothy Nichols; Eugenio Montini; Luigi Naldini
Journal: Sci Transl Med Date: 2015-03-04 Impact factor: 17.956